Advent International is actively looking at opportunities in the Healthcare and Specialty Chemicals sectors
March 10th 2010 – Advent International, the global private equity firm, today announced that Christian Grenier has joined Advent as an operating partner to advise the firm on investment opportunities across the healthcare and speciality chemicals sectors. Advent’s deal team will seek to bring Christian’s valuable insight and sector expertise to bear when sourcing deals and developing portfolio companies.
Christian Grenier is an experienced manager, having worked for over 35 years in the healthcare and specialty chemicals sectors. He is currently CEO of BioVision, Europe’s largest life science forum. In 2000, Christian co-founded UroGene, a biotech company which develops urology products. Prior to that, he spent 13 years within the Aventis/Rhône-Poulenc group where he held three Executive Management roles in various divisions including specialty chemicals, animal and agro care.
Christian holds diplomas from ESCP and Insead and began his career with strategic consulting firm McKinsey and Co and then Airbus Industries. He also serves as Non-Executive Chairman for several industrial and biotech companies, including Laboratoire Delpharm, UroGene SA and Neorphys SAS.
Guillaume Darbon, Managing Director of Advent International in France, commented, “We are delighted to welcome Christian Grenier to our Operating Partner programme. Advent is an active investor in the healthcare and specialty chemicals sectors across the world and we believe that the current market environment in France presents many exciting investment opportunities. The depth of experience that Christian brings to Advent will enhance our capability to pursue such opportunities as well as provide support to our portfolio companies globally.”
Commenting on his new role, Christian Grenier said, “I am delighted to be formalising my partnership with Advent, having built a strong relationship with the healthcare and specialty chemicals teams over the last few months. Advent’s reputation as an investor, notably the real expertise of its teams managing its portfolio companies and their ambitions for these key sectors in France, convinced me”
Advent has been an active investor in the healthcare sector for the last 25 years and has funded over 25 companies worldwide. Most recently Advent acquired Centrul Medical Unirea (CMU), a leading chain of medical clinics in Romania. Current investments also include MEDIAN Kliniken, the leading independent rehabilitation care provider in Germany, and Craegmoor Healthcare, the UK’s largest independent provider of specialist care for adults and younger people. Advent’s previous investments include the generic pharmaceutical businesses Viatris and pharmaceutical manufacturer Terapia.
Christian Grenier will work alongside two other Advent healthcare advisors: Jean-Louis Segura for healthcare services and Luciano Cattani for medical technology and devices. Jean-Louis Segura was formerly head of the regional hospitalisation agency in Burgundy and the director of the Cancéropole project in Toulouse. Luciano Cattani, is currently an Executive Vice President of Stryker Corporation and vice-chairman of the Eucomed trade association.
In the specialty chemicals sector Advent has a broad experience and has invested in more than 20 companies globally. Advent’s recent investments in the sector include: Oxea, one of the world's leading producers of Oxo chemicals; Deutek, Romania’s largest decorative paints producer; and Vinnolit, Germany’s leading specialty PVC producer.
Advent’s Operating Partner Programme involves business leaders from a range of sectors working as consultants to the firm in a variety of ways: sourcing investment opportunities, assisting with the due diligence process and advising on the strategic and operational development of portfolio companies. The use of operating partners is a fundamental and long-established element of Advent’s highly operational approach to investing. The programme currently includes over 70 high-level individuals, many of whom have been involved in multiple Advent investments.